Five-year CARTITUDE-2 data show 50% of 20 early-line relapsed multiple myeloma patients remained alive and progression-free after a single Carvykti infusion without maintenance therapy, strengthening the case for using CAR-T before heavily pretreated disease.
CARVYKTI keeps half of CARTITUDE-2 patients progression-free and treatment-free at five years after one infusion. See what the data mean.
European regulators have backed Tecvayli monotherapy after only one prior multiple myeloma treatment, potentially transforming Johnson & Johnson’s BCMA bispecific from a late-line therapy into a much larger second-line franchise.
Johnson & Johnson’s CARVYKTI shows 80 percent treatment-free survival at 30 months in second-line myeloma. Is CAR-T moving to earlier use?